It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The constant emergence of SARS-CoV-2 variants continues to impair the efficacy of existing neutralizing antibodies, especially XBB.1.5 and EG.5, which showed exceptional immune evasion properties. Here, we identify a highly conserved neutralizing epitope targeted by a broad-spectrum neutralizing antibody BA7535, which demonstrates high neutralization potency against not only previous variants, such as Alpha, Beta, Gamma, Delta and Omicron BA.1-BA.5, but also more recently emerged Omicron subvariants, including BF.7, CH.1.1, XBB.1, XBB.1.5, XBB.1.9.1, EG.5. Structural analysis of the Omicron Spike trimer with BA7535-Fab using cryo-EM indicates that BA7535 recognizes a highly conserved cryptic receptor-binding domain (RBD) epitope, avoiding most of the mutational hot spots in RBD. Furthermore, structural simulation based on the interaction of BA7535-Fab/RBD complexes dissects the broadly neutralizing effect of BA7535 against latest variants. Therapeutic and prophylactic treatment with BA7535 alone or in combination with BA7208 protected female mice from the circulating Omicron BA.5 and XBB.1 variant infection, suggesting the highly conserved neutralizing epitope serves as a potential target for developing highly potent therapeutic antibodies and vaccines.
Most recent SARS-CoV-2 variants showed exceptional immune evasion properties. Here, the authors identify a highly conserved epitope within the RBD targeted by a broad spectrum neutralizing antibody BA7535 that shows therapeutic antiviral potency in mouse studies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China (GRID:grid.470124.4); The Second Affiliated Hospital of Guangzhou Medical University, Clinical Laboratory Medicine Department, Guangzhou, China (GRID:grid.412534.5); Guangzhou Medical University, GMU-GIBH Joint School of Life Sciences, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
2 Southern University of Science and Technology, Cryo-electron Microscopy Center, Shenzhen, China (GRID:grid.263817.9) (ISNI:0000 0004 1773 1790)
3 Shandong Boan Biotechnology Co., Ltd., Antibody Research and Development Center, Yantai, China (GRID:grid.263817.9)
4 National Institutes for Food and Drug Control (NIFDC), Division of Monoclonal Antibodies, Institute for Biological Product Control, Beijing, China (GRID:grid.410749.f) (ISNI:0000 0004 0577 6238)
5 Shandong Boan Biotechnology Co., Ltd., Antibody Research and Development Center, Yantai, China (GRID:grid.410749.f)
6 the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China (GRID:grid.470124.4)
7 Shandong Boan Biotechnology Co., Ltd., Antibody Research and Development Center, Yantai, China (GRID:grid.470124.4)
8 Guangzhou Customs District Technology Centre, Health and Quarantine Laboratory, Guangzhou, China (GRID:grid.470124.4)
9 the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China (GRID:grid.470124.4); Bio-Island, Guangzhou National Laboratory, Guangzhou, China (GRID:grid.470124.4); ShanghaiTech University, Shanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, Shanghai, China (GRID:grid.440637.2) (ISNI:0000 0004 4657 8879); Southern University of Science and Technology, Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital; The Second Affiliated Hospital, School of Medicine, Shenzhen, China (GRID:grid.263817.9) (ISNI:0000 0004 1773 1790)